The biology and clinical development of MEK inhibitors for cancer.
about
Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells.Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study.MEK and ERK Kinase Inhibitors Increase Circulating Ceruloplasmin and Cause Green Serum in Rats.The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment.MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
P2860
The biology and clinical development of MEK inhibitors for cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The biology and clinical development of MEK inhibitors for cancer.
@en
type
label
The biology and clinical development of MEK inhibitors for cancer.
@en
prefLabel
The biology and clinical development of MEK inhibitors for cancer.
@en
P2093
P2860
P1433
P1476
The biology and clinical development of MEK inhibitors for cancer.
@en
P2093
Geoffrey I Shapiro
Jason J Luke
Patrick A Ott
P2860
P2888
P304
P356
10.1007/S40265-014-0315-4
P577
2014-12-01T00:00:00Z
P6179
1045041575